ImmuPharma plc (LON:IMM – Get Free Report)’s stock price fell 25.5% on Monday . The stock traded as low as GBX 6.76 and last traded at GBX 7.27. 24,809,416 shares traded hands during trading, an increase of 211% from the average session volume of 7,971,064 shares. The stock had previously closed at GBX 9.76.
ImmuPharma Trading Up 8.8%
The company has a 50 day moving average of GBX 10.80 and a 200-day moving average of GBX 5.87. The firm has a market capitalization of £37.20 million, a P/E ratio of -8.31 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- How Technical Indicators Can Help You Find Oversold Stocks
- Insiders Are Snapping Up This AI Stock—Is a Big Bounce Coming?
- What is the S&P/TSX Index?
- These 2 Energy Titans Just Scored Major Wins to Close Out November
- Why Are Stock Sectors Important to Successful Investing?
- Analog Devices Moves Higher as Super-Cycle Gains Momentum
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
